Biotech partner drops GlaxoSmithKline’s adjuvant as it moves Covid-19 vaccine into PhII/III, citing ‘manufacturing considerations’

When GlaxoSmithKline revealed that its Sanofi-partnered recombinant protein-based Covid-19 vaccine program was running into a major delay, the pharma giant tucked in a paragraph noting the other lower-profile collaborations it had going on that utilized its pandemic adjuvant.

One of those partnerships, though, is now coming to an end.